Cargando…

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Lee, Seung-Hoon, Jeon, Sang Won, Shin, Cheolmin, Pae, Chi-Un, Patkar, Ashwin A., Masand, Prakash S., An, Hyonggin, Han, Changsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neuropsychiatric Association 2022
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233947/ https://www.ncbi.nlm.nih.gov/pubmed/35753689 http://dx.doi.org/10.30773/pi.2021.0368e

Ejemplares similares

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2023)

Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial
por: Oh, K.-S., et al.
Publicado: (2022)

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2019)

Investigating the effectiveness of a smart mental health intervention (inMind) for stress reduction during pharmacological treatment for mild to moderate major depressive disorders: Study protocol for a randomized control trial
por: Kim, Junhyung, et al.
Publicado: (2023)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2018)

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2020)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway
por: Cocchi, Enrico, et al.
Publicado: (2016)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
por: Wang, Sheng-Min, et al.
Publicado: (2018)

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
por: Han, Changsu, et al.
Publicado: (2019)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
por: Marks, David M., et al.
Publicado: (2009)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram
por: Chakroborty, Shreaya, et al.
Publicado: (2017)

The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia
por: Porcelli, Stefano, et al.
Publicado: (2015)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

Desvenlafaxine
por: Andrade, Chittaranjan
Publicado: (2009)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009)

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
por: Maity, Nabakumar, et al.
Publicado: (2014)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
por: Calabrò, Marco, et al.
Publicado: (2019)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

Distinct Effects of Escitalopram and Vortioxetine on Astroglial L-Glutamate Release Associated with Connexin43
por: Shiroyama, Takashi, et al.
Publicado: (2021)

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
por: Calabrò, Marco, et al.
Publicado: (2018)

Normative data and psychometric properties of the Patient Health Questionnaire-9 in a nationally representative Korean population
por: Shin, Cheolmin, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial
por: Mahajan, Sonia Shinde, et al.
Publicado: (2019)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

Epistatic Interactions between CREB and CREM Variants in Affective Disorder
por: Chiesa, Alberto, et al.
Publicado: (2014)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1t9okhed7h1l8dvvtokurvvqsi